Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas
Publisher DOI
PubMed ID
21425137
Abstract
Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.
Date Issued
2011
Publication Type
Article
Language(s)
en
Author(s)
Grozinsky-Glasberg, Simona | |
Barak, Dganit | |
Fraenkel, Merav | |
Müeller-Brand, Jan | |
Eckstein, Joseph | |
Applebaum, Liat | |
Shimon, Ilan | |
Gross, David J |
Additional Credits
Journal
Cancer
Publisher
John Wiley & Sons
ISSN
0008-543X
Access(Rights)
metadata.only